GlobeNewsWire
14 Jun 2026, 23:30 UTC · 2h ago
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
14 Jun 2026, 23:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Olverembatinib demonstrated deep and durable responses in CML-CP patients resistant or intolerant to first-line TKI therapy, supporting its potential as a second-line treatment. — Establishing a clear second-line treatment position for a core asset expands the addressable market and revenue potential.
+0.60Updated data from the Phase III POLARIS-1 study for olverembatinib in Ph+ ALL further validated its deep response rate and manageable safety profile. — Positive Phase III results in a registrational study significantly increase the probability of regulatory approval and commercialization.
+0.50The combination of olverembatinib and lisaftoclax showed encouraging clinical data in pediatric patients with relapsed/refractory Ph+ ALL. — Successful combination therapy data creates new therapeutic indications and strengthens the competitive moat of the company's portfolio.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Registrational Phase II data for lisaftoclax in CLL/SLL provided insights for optimizing individualized dosing regimens. — Optimizing dosing is a critical step toward successful registration and maximizing patient outcomes in a key indication.
+0.30Real-world data on lisaftoclax in myeloid neoplasms provided evidence of the drug's clinical utility. — Real-world evidence supports broader adoption by clinicians beyond controlled clinical trial settings.
+0.20Which stocks this story touches
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
19h ago
